Risk factors

Palvella Therapeutics (PVLA) risk factors

Item 1A of every Palvella Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open PVLA in Gloom →
Palvella Therapeutics' chart, financials and news, free in your browser.Open PVLA in Gloom →
  • FY2025 10-K risk factors
    83 risks82 new95 dropped1 reworded

    Palvella Therapeutics faces significant financial risks advancing QTORIN rapamycin for rare skin diseases through clinical trials without approved commercial products.

    Filed Mar 31, 2026
  • FY2024 10-K risk factors
    96 risks

    Palvella is an early-stage biopharmaceutical company with zero product revenue and substantial historical operating losses.

    Filed Mar 31, 2025